{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-020116","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.735244+00:00","generated_at":"2026-06-24T00:44:14.956833+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AcelRx Q2 net income $70.7M on $84.1M debt gain; revenue $0.6M","bullets":["Net income of $70.7M ($0.48 diluted EPS) vs net loss of $9.9M in Q2 2021, driven by $84.1M gain on extinguishment of royalty monetization liability.","Revenue $0.6M; commercial ex-DoD unit sales up 133% YoY; total DSUVIA units 10,600.","Realigned cost structure reducing headcount ~40%, generating expected annual savings of $9M.","Cash and short-term investments $27.9M as of June 30, 2022; 983 DSUVIA formulary approvals achieved.","Niyad supply chain progress; targeting Emergency Use Authorization in 2023; DZUVEO EU launch on track for Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-020116","json":"https://secwatch.observer/filing/0001437749-22-020116.json","markdown":"https://secwatch.observer/filing/0001437749-22-020116.md","text":"https://secwatch.observer/filing/0001437749-22-020116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774922020116/0001437749-22-020116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774922020116/acrx20220810_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:44:14.956833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}